Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 3/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.30 |
| ▸ | CDK9 | P50750 | 3/20 | 0.30 |
| ▸ | CCNK | O75909 | 2/20 | 0.30 |
| ▸ | CDK2 | P24941 | 2/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23114318 | 0.86 | CHRNA7 (0.40) | ESR1ESR2CHRNA7NR1H2NR1H3 | |
| SCHEMBL24837386 | 0.84 | ESR1 (0.36) | ESR1ESR2CHRNA7NR1H2NR1H3 | |
| SCHEMBL25825557 | 0.81 | PANK3 (0.38) | ESR1ESR2CHRNA7NR1H2NR1H3 | |
| SCHEMBL14552838 | 0.77 | TSHR (0.41) | NR1H2NR1H3CCNT1CDK9CCNK | |
| SCHEMBL2442810 | 0.76 | ALDH1A1 (0.46) | — | |
| SCHEMBL21267702 | 0.75 | KMT2A (0.45) | CHRNA7NR1H2NR1H3 | |
| SCHEMBL20994112 | 0.75 | ESR1 (0.39) | ESR1ESR2CHRNA7NR1H2NR1H3 | |
| SCHEMBL18291549 | 0.74 | GRIA2 (0.38) | ESR1ESR2CHRNA7NR1H2NR1H3 | |
| SCHEMBL24500280 | 0.74 | CHRNA7 (0.44) | CHRNA7APLNRCDK2CDK1 | |
| SCHEMBL5513086 | 0.72 | KDM4E (0.43) | ESR1ESR2PANK3PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | ENPP1, ENPP3, SMPD1 | ESR1 3303/4885ESR2 1810/4885CHRNA7 3754/4885 |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | ENPP1, ENPP3, SMPD1 | ESR1 3303/4885ESR2 1810/4885CHRNA7 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.